1.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NIMH
Protocol IDs: R01 MH071580, DATR A3-NSS, NCT00352885
|
|
2.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EPC2008-02, NCT01347996
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12PLK01, NCT01683188
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: CNR-9506, EU-95024, NCT00002702
|
|
5.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: COG-ANBL0032, ANBL0032, COG-P9842, NCT00026312
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: P030441, AOM 03142, NCT00149162
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: Other
Protocol IDs: BRD/04/1-D, NCT00200577
|
|
8.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GMPE, NCT01256801
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: 27MD02, NCT00154713
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2225.00, NCI-2010-00108, K12CA076930, FHCRC-2225.00, IR-6881, BMS-CA184-062, NCT00871481
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090082, 09-C-0082, NCT00924326
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I 145208, NCT01038778
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Luc 10-002, NCT01191034
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PH-L19IL2GEM-01/07, 2007-001609-81, NCT01198522
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110013, 11-C-0013, NCT01218867
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: DCCIK001, NCT01235845
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: GFM-Aza-ceplene, NCT01324960
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2011-0073, NCT01409174
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110266, 11-C-0266, NCT01454596
|
|
21.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 11-080, NCT01550367
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120111, 12-C-0111, NCT01583686
|
|
23.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 8 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: DIV-NB-201, NCT01592045
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2011-0847, NCT01603212
|
|
25.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2498.00, NCI-2011-03362, P01CA018029, NCT01640301
|
Mobile | Español
